新型冠狀病毒感染疾病 (COVID-19) 檢驗的全球市場，最新版 (2021年):分子、抗原檢驗市場，治療，突然變異，家庭檢驗，其他趨勢
COVID-19 Testing Market Update 2021: Molecular & Antigen Markets, Procedures, Mutations, Home Tests, and Other Trends
|出版日期||內容資訊||英文 72 Pages
|新型冠狀病毒感染疾病 (COVID-19) 檢驗的全球市場，最新版 (2021年):分子、抗原檢驗市場，治療，突然變異，家庭檢驗，其他趨勢 COVID-19 Testing Market Update 2021: Molecular & Antigen Markets, Procedures, Mutations, Home Tests, and Other Trends|
|出版日期: 2021年02月16日||內容資訊: 英文 72 Pages||
本報告提供全球新型冠狀病毒感染疾病 (COVID-19) 用各種檢驗的市場相關分析，疾病概要和市場基本結構，背景情況和主要的影響要素，主要的檢驗藥的開發、上市情形，市場規模趨勢預測 (2020年∼2021年)，各地區的詳細趨勢 (北美、歐洲、亞洲等)，主要供應商的簡介等調查。
As the unfortunate milestone of one full year of the global COVID-19 pandemic worldwide is reached, the diagnostic industry has been changed, perhaps permanently. Hundreds of test products are on the market to detect the virus, both for its presence and immune response. And billions of dollars have been added to the in vitro diagnostic market. Companies have doubled and tripled revenues, bought new companies, increased manufacturing, shifted focus to infectious diseases and launched new products.
"A 38 Billion Dollar Market for COVID-19 Test Products: Molecular, Antigen, and Antibody Tests."
New features have been added to tests, such us variant and mutation detection, combination with flu and RSV, more specific [neutralizing] antibody detection, or ultra-large volume capacities. A new category of testing has been crated than in a year is rivaling all others in volume. And with it, market changes a shift of top categories in IVD towards infectious disease testing and other COVID-19 related tests. This report, COVID-19 Testing Update 2021, provides the most current analyst assessment of the market for COVID-19 testing. As part of its report data, the report includes:
New companies have entered the diagnostics market sensing opportunities and to contribute to the emergency need. And some companies have grown and make expansions and acquisitions. Kalorama looks at these companies and also the major IVD players and how COVID-19 has affected their performance.
This is an important time to look at this market as several trends that could change the direction of diagnostic take hold:
Just in the last two months, COVID-19 has affected considerable change at diagnostic companies. One comapny has acquisitions, fortified with cash from increased sales of test kits. Others launched home testing kits. One cash-negative company was made cash-postive, while another doubled its test capacity and yet another tripled sales of instruments. Companies not in infectious disease testing are quickly pivoting to it. The first test for asymptomatic patients was approved, and new innovative features such as saliva sampling or ultra-high throughput even CRISPR are being added to tests.
Companies mentioned in the report include:
As well as many other companies.